CD13 nanoCAR circRNAs
/ Citil Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
CD8 nanobody-targeted lipid nanoparticles encapsulating CD13 nanoCAR circular RNAs for in situ CAR-T cell eradication of acute myeloid leukemia
(AACR 2026)
- "We then assayed and selected the THP-1 human AML cell line showing high CD13 expression and low nonspecific T cell killing in vitro. In an immunodeficient NPG CDX mouse model, CD8 nanobody-targeted lipid nanoparticles encapsulating CD13 nanoCAR circRNAs exhibit specific and effective in vivo killing of a subcutaneously engrafted THP-1 tumor."
CAR T-Cell Therapy • Circular RNA • IO biomarker • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • ANPEP • CD123 • CD33 • CD8 • IL3RA
1 to 1
Of
1
Go to page
1